Storia in 2 fonti

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Regenxbio (NASDAQ:RGNX)

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.

Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal d...